Viemed (VMD) Q1 2026 earnings review
Diversification Drives Top Line, But Core Stagnates
Viemed's first quarter showed the power of its diversification strategy, with revenue growing 28% YoY to $75.4M. However, the top-line growth did not trickle down to the bottom line—Net Income was completely flat YoY at $2.6M, weighed down by higher SG&A costs. While the Sleep and Maternal Health segments are accelerating, the core Ventilator business has essentially stalled, shrinking slightly on a sequential basis. The company raised the bottom end of its FY26 revenue guidance, citing structural shifts toward less capital-intensive services, but the lack of earnings growth despite massive volume gains remains a friction point.
🐂 Bull Case
Management lowered their Net CapEx guidance from 10-11.5% to 9-10.5% of revenue, signaling that the shift toward sleep and maternal health requires significantly less capital to scale, freeing up more cash flow.
PAP Therapy patient counts exploded by 57% YoY. The company is proving it can capture meaningful market share outside of its historical core ventilator market.
🐻 Bear Case
Ventilator patients grew just 2% YoY and actually declined sequentially from Q4. As this segment carries historically higher margins, its stagnation is pressuring overall profitability.
Despite adding $16.3M in incremental YoY revenue, Net Income was flat and Adjusted EBITDA grew only 12%. SG&A expenses surged, eating up the gross profit gains.
⚖️ Verdict: ⚪
Neutral. Viemed is successfully executing its transition from a pure-play ventilator company to a diversified home care provider, which derisks the business. However, the failure to translate 28% revenue growth into net income growth shows the cost of this transition.
Key Themes
Sleep Segment Acceleration
The company's push into the sleep market is generating massive volume. PAP Therapy patients reached 35,938, accelerating 57% YoY and 4% sequentially. This service line now accounts for 16% of Q1 total revenue (up from 14% a year ago). The volume of new setups provides a clear line of sight to future high-margin resupply revenues, making this the primary growth engine for the foreseeable future.
Sleep Resupply Dropped Sequentially
In a reversing trend that contradicts the bullish sleep narrative, Sleep Resupply patients actually dropped 8% sequentially (from 36,561 in 25Q4 down to 33,661 in 26Q1). Resupply is the recurring, higher-margin tail of the sleep business. If new therapy setups do not reliably convert into long-term resupply patients, the profitability of this segment will structurally degrade.
Ventilator Business Stagnation
The core ventilator business is decelerating significantly. Vent patient count grew a meager 2% YoY to 12,089, and declined slightly from 12,259 at the end of 2025. While management has previously cited 'friction' from new National Coverage Determination (NCD) rules and documentation requirements, this segment's stall is the main reason margins are struggling to expand.
Margin Profile is Shifting
Gross margin remains relatively stable (57% vs 56% a year ago), but operating expenses are dragging down the bottom line. SG&A jumped from $28.4M to $34.8M YoY. Management has previously noted that sleep and maternal health carry a different margin profile than ventilator rentals, requiring higher initial operational lift. SG&A scaling through technology will be critical to returning to profit growth.
Structurally Lower Capital Intensity
The business model is actively shifting from heavy CapEx to lighter, service-oriented lines. Management updated its Net CapEx guidance to 9%-10.5% of revenue, down from previous expectations. This shift structurally improves Free Cash Flow generation over time, allowing the company to self-fund share repurchases and pay down debt without accessing equity markets.
Other KPIs
Decelerating from recent quarters ($10.8M in 25Q4), but up significantly over the trailing twelve months ($36.3M). The cash flow was sufficient to fund $1.4M in share buybacks and $3.2M in term loan repayments while maintaining a healthy cash balance of $9.8M.
Stable. Represents a 12% YoY increase, though margins slipped. Management noted that the prior-year period (25Q1) included a $2.7M non-recurring gain on property disposal, making the core operational YoY comparison stronger than the headline numbers imply.
Guidance
Accelerating. The guidance range was narrowed and the bottom end was raised (previously $310 - $320 million). At the midpoint ($316M), this implies ~17% YoY growth over FY25's $270M, driven by favorable trends in new patient starts.
Stable. The guidance was reaffirmed. The midpoint ($67M) implies ~9% YoY growth over FY25's $61.4M, lagging revenue growth due to the mix shift toward lower-margin segments and a difficult comp against a non-recurring 2025 equipment gain.
Decelerating. This is a positive development. Guidance was lowered from the previous 10.0% - 11.5% range. Management cited the continued shift toward less capital-intensive service lines, which directly supports future free cash flow generation.
Key Questions
Sleep Resupply Disconnect
PAP Therapy patient counts grew 4% sequentially, yet Sleep Resupply patient counts fell 8%. What drove this sudden disconnect, and what are you doing to ensure new sleep patients convert reliably to the recurring resupply program?
Ventilator Segment Outlook
With ventilator patient growth now effectively flat on a sequential basis, do you view this as a permanent plateau following the NCD rule changes, or do you expect a re-acceleration in the back half of the year?
Margin Target Viability
Given the 22% increase in SG&A expenses YoY, what specific AI or technological initiatives are currently being deployed to gain operational leverage and stop margin compression in the lower-margin sleep segments?